Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body ...

Heritage Global Inc (NASDAQ:HGBL). has entered into a Mortgage Loan Agreement with C3bank, National Association for a $4.1 million term loan. The loan will fund the purchase of a property that will ...

The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...